Products
Glide Pharma is building a pipeline of in-house and partnered products based on its proprietary Glide technology. Glide is an innovative new needle-free injection system that allows the delivery of drugs, vaccines and other active pharmaceutical ingredients in solid form. Glide offers significant benefits and opportunities to drug developers, healthcare providers, patients and their carers.
Glide Pharma’s first product will be a needle-free injectable formulation of sumatriptan to treat migraine. The Glide technology will give migraine sufferers a simple, clean and easy to use treatment option that offers rapid and consistent relief to those who need a more reliable and faster action than tablet or nasal formulations can provide.
The chart below summarizes current development programmes underway:
Product Code Number |
Application |
Funding Source |
Development Stage |
GP01 |
Sumatriptan |
Internal |
Preparing for clinical study based on a bioequivalence strategy |
GP02 |
Octreotide |
Internal |
Preparing for clinical study based on a bioequivalence strategy |
GP03 |
Fentanyl |
Internal |
Proof of concept in non-clinical model |
GP51 |
Undisclosed biologic |
Partnered |
Feasibility studies – second phase |
GP52 |
Undisclosed biologic |
Partnered |
Feasibility study |
